Reverse-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
In the USA and other countries it was discontinued gradually after the introduction of the electroconvulsive therapy during the 1940s and the first neuroleptic drugs during the 1950s. Dr. Sakel died from heart failure on December 2, 1957, in New York City, NY, USA.
Huntington's disease is a trinucleotide repeat disorder caused by trinucleotide repeat expansion in the first exon of the huntingtin gene (HTT), which encodes the huntingtin protein (HTT). HTT may also be referred to as the HD gene or, historically, IT15 (interesting transcript 15). It is located on the short arm of chromosome 4 at 4p16.3. The trinucleotide repeat region of HTT is primarily composed of CAG, which encodes the amino acid glutamine; thus, the resulting protein contains a polyglutamine tract (polyQ tract). The number of repeats varies in length between individuals and may change length between generations. When the length of this repeated section exceeds a certain threshold, it produces mutant huntingtin protein (mHTT). In turn, mHTT has toxic gains and losses of function which negatively impact cell function and lead to disease. The Huntington's disease mutation is genetically dominant and almost fully penetrant; a single mutant HTT allele from either parent is sufficient to cause the disease. Because the rate of mutation is higher in sperm cells, males are more likely to transmit expanded HTT alleles to their offspring.
=== Externally directed self-assembly === The natural ability of nanoparticles to self-assemble can be replicated in systems that do not intrinsically or spontaneously self-assemble. Directed self-assembly (DSA) attempts to mimic the chemical properties of self-assembling systems, while simultaneously controlling the thermodynamic system to maximize self-assembly. However, many common routes to externally promote self-assembly occur far from thermodynamic equilibrium and are rather described by kinetic theories.
=== von Reumont et al. (2012) === In a 2012 molecular study, von Reumont et al. challenge the monophyly of Vericrustacea: they present four versions of Pancrustacea cladogram (figures 1–4), and in all four figures Remipedia is a sister group to Hexapoda, and Branchiopoda is a sister group to (Remipedia + Hexapoda). Thus, their data strongly suggest that Branchiopoda is more closely related to Hexapoda and Remipedia than to Multicrustacea. Based on these data, they propose the following scenario of evolution of Branchiopoda, Remipedia and Hexapoda: under the impact of predatory fishes their common ancestors go to the littoral zone, then ancestors of Branchiopoda go to the ephemeral freshwater habitat, whereas ancestors of Remipedia go to the anchialine cave, and ancestors of Hexapoda go to the land.
Sources: en.wikipedia.org
On 1 March, the Department of Food and Veterinary of Lithuania announced that horse meat was found in three canned beef brands sold by Latvian company Kuršu Zeme. Canned beef made by the Latvian company was removed from sale in Lithuania. === Wiljo Import en Export B.V. and Vleesgroothandel Willy Selten B.V. === On 10 April 2013, it was reported that two Dutch trading companies, owned by the same person whom food safety officials had previously investigated, may have supplied 50,000 metric tonnes of adulterated beef containing horse meat since January 2011. On 7 February 2013, it was revealed by the Food Standards Agency that the Findus beef lasagne range in the UK, France, Norway, and Sweden, and the shepherd's pie and moussaka ranges in France, contained horse meat without proper declaration or official scrutiny. The contamination may have gone on since summer 2012 according to a leaked document.
{\displaystyle {\ce {{^{238}_{92}U}+{}_{0}^{1}n->{}_{92}^{239}U->[\beta ^{-}][23.5\ {\ce {min}}]{}_{93}^{239}Np->[\beta ^{-}][2.3\ {\ce {days}}]{}_{94}^{239}Pu}}\left({\ce {->[\alpha ][2.4\cdot 10^{4}\ {\ce {years}}]}}\right){\ce {^{235}_{92}U}}}
== Reviews == Popp, Prank D. (1975). "The Chemistry of Isatin". Advances in Heterocyclic Chemistry Volume 18. Vol. 18. pp. 1–58. doi:10.1016/S0065-2725(08)60127-0. ISBN 978-0-12-020618-6. Silva, Joaquim F. M. da; Garden, Simon J.; Pinto, Angelo C. (June 2001). "The chemistry of isatins: a review from 1975 to 1999". Journal of the Brazilian Chemical Society. 12 (3): 273–324. doi:10.1590/S0103-50532001000300002. Mesropyan, E. G.; Avetisyan, A. A. (2009). "New isatin derivatives". Russian Journal of Organic Chemistry. 45 (11): 1583. doi:10.1134/S1070428009110013. S2CID 97341279. Varun, Varun; Sonam, Sonam; Kakkar, Rita (2019). "Isatin and its derivatives: a survey of recent syntheses, reactions, and applications". MedChemComm. 10 (3): 351–368. doi:10.1039/C8MD00585K. PMC 6438150. PMID 30996856.
Sources: en.wikipedia.org
Metabolic studies indicate that NAD, once considered a stable molecule, is continuously turned over and used, requiring tight regulation to maintain metabolic homeostasis. NR utilization in mammals may involve both exogenous dietary sources and endogenous salvage processes that recycle intermediates. NR metabolism and the interactions of different NAD pathways continue to be studied. The NAM and NR pathways involve an amide group and are referred to as 'amidated' pathways. The pathways for de novo synthesis from tryptophan and from NA salvage are 'deamidated' pathways, which share a rate-limiting amidation enzyme NADsynthase1 (NADSYN). Disruptions or imbalances in NAD metabolism have been observed in many disease conditions, and the possibility of restoring NAD levels by administering NAD precursors is an area of interest for researchers.
== Brief history == Over the years many variations of the instrument have been made. In the beginning during the 1960s there was the study of flowing afterglow plasma. This study was done by Eldon Ferguson, Art Schmeltekopf and Fred Fehsenfeld at National Bureau of Standards in Boulder, Colorado. Then in the 1970s it was flowing drift tube, flowing afterglow Langmuir probe (FALP), and variable temperature flowing afterglow Langmuir probe (VT-FALP). With the addition of the drift tube the kinetics of a reaction could be studied in the gas phase. With the flowing afterglow Langmuir probe the electron density within the reaction region of the drift tube can be studied. With the VT-FALP version of flowing afterglow the reactions temperature dependence could be studied. Now in the 2000s the ambient version of flowing afterglow mass spectrometry is flowing atmospheric pressure afterglow mass spectrometry (FAPA-MS).The FAPA allows for simple or no sample preparations but the humidity of the instrument's environment may have an effect on a sample fragmentation pattern. Since the cost of helium is steady rising some have started to use alternative methods with ambient flowing afterglow to conserve resources. Instead of using continuously flowing afterglow helium some use interrupted helium flow to conserve gas and Schlieren imaging to maximize the molecular ions produced and the instrument step-up.
=== 2008–2011: Black Gives Way to Blue and death of Mike Starr === Blabbermouth.net reported on September 5, 2008, that Alice in Chains would enter the studio that October to begin recording a new album for a summer 2009 release. On September 14, 2008, Alice in Chains performed at halftime during the Seattle Seahawks vs San Francisco 49ers game at the Qwest Field (now named Lumen Field ) in Seattle. The 12-minute performance for a crowd of 67,000 people featured a cover of Led Zeppelin's "Kashmir" accompanied by the Northwest Symphony Orchestra. In October 2008, Alice in Chains began recording its fourth studio album at the Foo Fighters' Studio 606 in Los Angeles with producer Nick Raskulinecz. The band did not have a record label at the time and the album was funded by Jerry Cantrell and Sean Kinney. At the Revolver Golden God Awards, Cantrell said that the group had finished recording on March 18, 2009, and were mixing the album for a September release. The recording process was completed on Cantrell's 43rd birthday and also the same day that William DuVall's son was born. In April 2009, it was reported that the new Alice in Chains album would be released by Virgin/EMI, making it the band's first label change in its 20-plus year career. David Benveniste and his Velvet Hammer Music & Management Group began co-managing the band with Susan Silver, marking the most recent change of management and latest development to date.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.